This is the space that viralytics played in and was purchased by Merck as it appeared to compliment keytruda with low safety issues.
The interesting thing about immunotherapy and stem cells is they appear to work better in patients with more severe forms of the respective diseases. It makes me wonder if that idea was utilised in the heart trial design. Perhaps we might see better results in the stage 3 vs 2 patients.
This is the space that viralytics played in and was purchased by...
-
- There are more pages in this discussion • 16,987 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |